Cordis recently announced the first-in-human use of the Radianz radial peripheral system by Jihad Mustapha at Advanced Cardiac & Vascular Centers (ACV) in Grand Rapids, USA.
The Radianz radial peripheral system solution includes Brite Tip Radianz guiding sheath used to optimise lower extremity lesion access, the Saberx Radianz percutaneous transluminal angioplasty (PTA) catheter to facilitate treatment, and the S.M.A.R.T. Radianz vascular stent system to help maintain patency for lasting favourable outcomes.
The system is purposely engineered for radial access, which, the company claims, is proven to produce fewer vascular complications and higher patient satisfaction than femoral approaches.
Mustapha, chief executive officer and director of endovascular intervention at Advanced Cardiac & Vascular Centers (ACV) for Amputation Prevention, commented: “My colleagues at ACV and I are pleased to have successfully performed the first procedures using the Radianz radial peripheral system. We believe this portfolio represents true innovation in meeting the need for radial access solutions for lower extremity intervention.”
“We are extremely pleased with the positive feedback from Dr Mustapha and proud that these first-in-human cases were performed so successfully and by such a highly esteemed physician,” said Cordis CEO Shar Matin. “When used as a comprehensive treatment solution for vascular disease, we believe the unique capabilities of the Radianz radial peripheral system have the potential to positively impact outcomes and improve quality of life for patients.”
According to a company press release, multiple studies have demonstrated overwhelming patient preference for radial versus femoral access. Studies also show that patient ambulation time can be reduced from hours to minutes, and that patients experience improved mobility and comfort from the outset, the release continues.
In addition to the clinical benefits of the Radianz radial peripheral system, Cordis claims that radial access can reduce the total cost of care. The company references a systematic review of 14 randomised controlled trials that found radial access lowered hospital costs in the USA by up to US$1,116 per procedure in duration-of-stay costs compared to femoral access.
The Radianz radial peripheral system portfolio is expected to launch later this year in the USA and in the near future in Japan, the company advises.